Flecainide successfully restored normal interventricular septal motion and improved ejection fraction in two infants with right-sided accessory pathway-induced dilated cardiomyopathy.
Case Report (n=2)
No
Does flecainide improve cardiac dyssynchrony and ejection fraction in infants with right-sided accessory pathway-induced dilated cardiomyopathy?
Flecainide may be an effective pharmacological alternative to catheter ablation for treating right-sided accessory pathway-induced dilated cardiomyopathy in infants.
Right-sided accessary pathways in patients with Wolff-Parkinson-White (WPW) syndrome may cause cardiac dyssynchrony and dilated cardiomyopathy, with a characteristic septal shape, irrespective of any supraventricular tachycardia episodes. We report on two infants (13 and 5 months), whose right-sided accessary pathway-induced dilated cardiomyopathy was successfully treated by flecainide for the first time. After the flecainide administration, an abnormal aneurysmal dilation of the basal interventricular septum was almost restored to normal, and the decreased ejection fraction recovered. Flecainide use may be an important therapeutic option for this entity to avoid catheter ablation during infancy.
Sekine et al. (Tue,) conducted a case report in Right-sided accessory pathway-induced dilated cardiomyopathy (n=2). Flecainide was evaluated on Improvement in cardiac dyssynchrony and ejection fraction. Flecainide successfully restored normal interventricular septal motion and improved ejection fraction in two infants with right-sided accessory pathway-induced dilated cardiomyopathy.